Roche

Antibodies
#License agreement #Roche #T cell engagers #Therapeutic Antibodies #Zymeworks

Roche licenses Zymeworks’ trispecific T cell engager targeting DLL3

Zymeworks has entered into a global license and collaboration agreement with Roche for the research, development and commercialisation of ZW209, a T cell engager targeting DLL3.  Under the agreement, Zymeworks is eligible to receive an upfront payment of $55 million, a $40 million payment upon initiation of… Read More

#Business & Investment #News

Weight loss concept
#Obesity #Roche #Type 2 diabetes #Weight loss #Zealand Pharma

Roche and Zealand drug shows 9.2% mean body weight reduction

Roche and Zealand Pharma have shared positive topline results from the Phase II ZUPREME-2 trial evaluating petrelintide versus placebo in people living with overweight or obesity and type 2 diabetes.  The trial met its primary endpoint, demonstrating that once-weekly subcutaneous injections of petrelintide (escalated every fourth week)… Read More

#News #Trending News

Bispecific antibodies
#Bispecific Antibodies #Collaboration #Dualitas Therapeutics #Roche

Roche and Dualitas Therapeutics agree $1b bispecific antibodies deal

Roche and Dualitas Therapeutics have announced a research collaboration and license agreement to advance novel bispecific antibodies for immunology & inflammation (I&I) diseases.  Under the terms of the agreement, Dualitas will receive $36.5 million upfront payment and may receive additional research, development and commercial milestone payments for… Read More

#Business & Investment #News

Bispecific antibodies
#Autoimmune disease #Bi- and trispecifics #Mergers and acquisitions #Roche

Roche acquires trispecific antibody for $1.5bn

Roche has acquired exclusive global rights to develop, manufacture, and commercialise SIM0660, a trispecific antibody targeting CD79a, CD19, and CD3, with therapeutic potential across B-cell-mediated diseases.  Under the terms of the agreement, developer Simcere Zaiming is eligible to receive up to $1.530 billion in total payments, including… Read More

#Business & Investment #News

Roche headquarters
#Artificial intelligence (AI) #Automation / robotics #Collaboration #NVIDIA #Roche

Roche leads AI drug discovery with new NVIDIA deal

Roche now operates the pharmaceutical industry’s largest announced hybrid-cloud AI factory, totalling more than 3,500 GPUs, following an expansion of its global AI infrastructure.  The company has deployed a large-scale AI factory powered by a full stack of the latest-generation NVIDIA accelerated computing and AI, marking the… Read More

#Business & Investment #News

Medical professional examining mammogram
#Breast cancer #Oncology #Phase III trial #Roche

Roche breast cancer study fails to meet primary objective

Roche has announced that its Phase III persevERA Breast Cancer study did not meet the primary objective of a statistically significant improvement in progression-free survival, but a numerical improvement was observed.  The trial assessed giredestrant in combination with palbociclib for people with oestrogen receptor (ER)-positive, human epidermal… Read More

#Cancer Research #News

Drugs targeting amyloid Plaque
#Alzheimer's #Neuroscience #Phase III trial #Roche

Roche’s AD study shows rapid clearance of amyloid plaques

Roche has shared new data from its Alzheimer’s development portfolio at the Alzheimer’s Association International Conference (AAIC) in Toronto, Canada.  Featured oral presentations include the latest results from the ongoing Phase Ib/IIa Brainshuttle Alzheimer’s disease (AD) study and design of the Phase III TRONTIER 1 and 2… Read More

#Editor's Choice #News

Cancer cells
#Breast cancer #European Commission #Oncology #Roche

EC approves Roche’s Itovebi for breast cancer subtype

The European Commission has approved Itovebi (inavolisib), in combination with palbociclib (Ibrance) and fulvestrant, for the treatment of adult patients with PIK3CA-mutated, oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. It is approved following recurrence on or within 12 months… Read More

#News #Regulatory

Neurons in the brain
#Alta Neuroscience #Alzheimer's #Biomarkers #Blood-based biomarkers #Diagnostics #Roche

How Roche is advancing Alzheimer’s research

DDW’s Megan Thomas speaks with Dr Maria-Magdalena Patru, Scientific Partner at Roche Diagnostics US, about how advances in Alzheimer’s disease (AD), particularly blood-based biomarkers (BBM), can enable earlier, more accurate, and accessible detection of the disease, supporting timely treatment and improved patient outcomes.  MT: Why is improving AD diagnostics crucial… Read More

#Exclusive Content

Gene sequence
#Drug discovery #High throughput screening #Lab technology #Next generation sequencing #Roche

Will Roche’s new SBX technology revolutionise sequencing?

Roche has unveiled its new breakthrough sequencing by expansion (SBX) technology, establishing a new category of next-generation sequencing.   According to the company, SBX chemistry, combined with an innovative sensor module, offers ultra-rapid, high-throughput sequencing that is both flexible and scalable for a broad range of applications. … Read More

#News #Trending News

Antibody drug conjugate
#Antibody drug conjugate (ADC) #Collaboration #Innovent #Lung cancer #Oncology #Roche #Small cell lung cancer

Roche pays $80 million for Innovent’s lung cancer ADC

Roche and Innovent Biologics have agreed a collaboration and exclusive license agreement to develop antibody drug conjugate (ADC) IBI3009 for advanced small cell lung cancer.  Under the agreement, the two parties will jointly focus on the early-stage development of the ADC candidate, after which Roche will take… Read More

#Business & Investment #News

Roche headquarters
#CAR-T #Cell therapy #Mergers and acquisitions #Poseida Therapeutics #Roche

Roche buys CAR-T specialist Poseida Therapeutics for $1.5bn

Roche has entered into a definitive merger agreement to acquire Poseida Therapeutics, a public clinical-stage biopharmaceutical company pioneering donor-derived CAR-T cell therapies.  Roche will acquire the company for $9 per share in cash at closing, representing a total equity value of approximately $1 billion.  Stockholders… Read More

#Business & Investment #News #Trending News

#AAV #Collaboration #Dyno Therapeutics #Gene therapy #Neurology #Roche

Roche and Dyno advance AAV gene therapies for neurological diseases

Dyno Therapeutics and Roche have announced a second research collaboration to develop adeno-associated virus (AAV) vectors for gene therapies targeting neurological diseases. Dyno and Roche previously agreed a research collaboration and license agreement for neurological diseases and liver-directed therapies in October 2020. Under the… Read More

#Business & Investment #News

CAR T-cells attacking a cancer cell
#CAR-T #Haematology #Myeloma #Oncology #Phase I trial #Poseida Therapeutics #Roche

Patients show 91% response to allogeneic CAR-T therapy

Investigators saw a 91% overall response rate (ORR) in patients with relapsed/refractory multiple myeloma (RRMM) following treatment with allogeneic CAR-T therapy P-BCMA-ALLO1 and lymphodepletion. The interim data from an ongoing Phase I trial in patients who have previously received three or more prior lines of therapy… Read More

#Cancer Research #News

Myeloma
#CAR-T #Cell and gene therapy #Cell therapy #FDA #Myeloma #Poseida Therapeutics #Roche

‘Off-the-shelf’ CAR-T secures FDA advanced therapy designation

The US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Roche and Poseida Therapeutics’ P-BCMA-ALLO1. P-BCMA-ALLO1 is an investigational stem cell memory T cell (TSCM)-based allogeneic CAR-T cell therapy in Phase I/Ib clinical development for the treatment of patients with… Read More

#News #Regulatory